Dec 9, 2024
1003(a)(iii) - Equity below $6 million and years of losses
NYSE American
RESOLVED
On June 12, 2026, AIM ImmunoTech was formally notified that it had regained compliance with NYSE American continued listing standards, successfully resolving its stockholders' equity deficiency under Section 1003(a)(iii) following capital raises in May and June 2026. As a result, the company is fully compliant and the below compliance (".BC") indicator was removed from its trading symbol, as reported on Filed At: 2026-06-15.
Dec 9, 2024
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
RESOLVED
On June 12, 2026, AIM ImmunoTech received confirmation from NYSE Regulation that it had regained compliance with continued listing standards, successfully resolving its deficiency under Section 1003(a)(ii) through warrant exercises and private placements conducted in May and June 2026. Consequently, the exchange removed the below-compliance (".BC") indicator from the company's trading symbol. Filed At: 2026-06-15.
Jun 15, 2025
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
RESOLVED
AIM ImmunoTech regained compliance with NYSE American listing standards, successfully resolving its stockholders' equity deficiencies under Section 1003(a)(i), (ii), and (iii) through warrant exercises and private placements completed in May and June 2026. NYSE Regulation formally notified the company of its compliant status on June 12, 2026, resulting in the removal of the ".BC" indicator from its trading symbol (Filed At: 2026-06-15).
Jun 16, 2025
1003(a)(i) - Equity below $2 million and years of losses
NYSE American
RESOLVED
On June 12, 2026, AIM ImmunoTech Inc. received confirmation from NYSE Regulation that it had resolved its stockholders' equity deficiency and regained full compliance with Section 1003(a)(i) of the NYSE American Company Guide following private placements and warrant exercises conducted in May and June 2026. The company announced the resolution on June 15, 2026, resulting in the removal of the below compliance (".BC") indicator from its common stock trading symbol, as reported in the Form 8-K Filed At: 2026-06-15.
Dec 10, 2024
1003(a)(ii) - Equity below $4 million and years of losses
NYSE American
RESOLVED
On June 12, 2026, AIM ImmunoTech received confirmation from NYSE Regulation that it had regained full compliance with NYSE American continued listing standards, successfully resolving its deficiency under Section 1003(a)(ii). As a result of bolstering its stockholders' equity through financing transactions in May and June 2026, the company had the ".BC" indicator removed from its trading symbol. Filed At: 2026-06-15.
Dec 10, 2024
1003(a)(iii) - Equity below $6 million and years of losses
NYSE American
RESOLVED
On June 12, 2026, AIM ImmunoTech received formal confirmation from NYSE Regulation that it had regained full compliance with continued listing standards, successfully resolving its stockholders' equity deficiency under Section 1003(a)(iii) (Equity below $6 million and years of losses). The company achieved compliance by raising its stockholders' equity above the $6.0 million minimum through a series of warrant exercise inducements and private placements closed in May and June 2026. Filed At: 2026-06-15.
